Liver Disease Biotechs' Stocks Crash on Eli Lilly's Mounjaro Data

New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.

Related Keywords

United States ,American ,Eli Lilly ,George Frey Bloomberg ,Andy Hsieh ,Josh Nathan Kazis ,Raymond James ,Eli Lilly Mounjaro ,William Blair ,Steven Seedhouse ,Daniel Skovronsky ,Intercept Pharmaceuticals ,Madrigal Pharmaceuticals ,Drug Administration ,Novo Nordisk ,Akero Therapeutics ,Viking Therapeutics ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Machinery ,Agricultural Machinery ,Healthcare Life Sciences ,Biopharmaceuticals ,Industrial Goods ,Financial Performance ,Share Price Movement Disruptions ,New Products Services ,Research Development ,Corporate Industrial News ,Products Services ,New Product Service Testing ,Cancer ,Political General News ,Health ,Medical Conditions ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Biotech And Pharma ,Markets ,North America ,News ,Eli Lilly Amp ,Rally ,Makro ,Novob Ko ,Dk Novo B ,89bio ,Getnb ,Mdgl ,Share Price Movement ,Disruptions ,New Products ,Services ,Research ,Development ,Corporate ,Industrial News ,Products ,New Product ,Service Testing ,Political ,General News ,Healthcare ,Life Sciences ,